Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy.
Casgevy vs. Lyfgenia: The Battle of the Sickle Cell Gene Therapies Has Begun 12/8/2023
Casgevy vs. Lyfgenia: The Battle of the Sickle Cell Gene Therapies Has Begun 12/8/2023
FDA Approves Two Gene Therapies for Sickle Cell, First CRISPR-Based Medicine 12/8/2023
Merck’s Keytruda Flops in Late-Stage Endometrial Carcinoma Study 12/8/2023
Vanda Buys US, Canadian Rights to J&J’s MS Drug Ponvory in $100M Deal 12/8/2023
Rebranded Spyre Therapeutics Secures $180M to Advance IBD Antibody Pipeline 12/8/2023
Daiichi Sankyo Reaches $182M Settlement with Novartis in Tafinlar Patent Case 12/8/2023
Axcella Health Becomes the Latest Flagship Company to Close its Doors 12/8/2023
Biopharma Funding, Deals Fall Sharply in 2023 in ‘Strategic’ Shift: PitchBook 12/8/2023
BMS Builds Case for Opdivo, Yervoy Combo in First-Line Colorectal Cancer 12/8/2023
Salus Optima, a leading provider in AI-enabled digital health and wellness solutions, and the Consumer Health division of Bayer have launched a strategic partnership to empower people on their healthy aging journey. The partnership elevates the shared aspiration of both companies to transform self-care by offering precision health solutions to enable consumers to better understand and make informed decisions about their own personal health and lifestyle choices.